200 related articles for article (PubMed ID: 25712682)
1. Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation.
Hasegawa M; Sinha RK; Kumar M; Alam M; Yin L; Raina D; Kharbanda A; Panchamoorthy G; Gupta D; Singh H; Kharbanda S; Kufe D
Clin Cancer Res; 2015 May; 21(10):2338-47. PubMed ID: 25712682
[TBL] [Abstract][Full Text] [Related]
2. Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9.
Kumar M; Gupta D; Singh G; Sharma S; Bhat M; Prashant CK; Dinda AK; Kharbanda S; Kufe D; Singh H
Cancer Res; 2014 Jun; 74(12):3271-81. PubMed ID: 24741005
[TBL] [Abstract][Full Text] [Related]
3. Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.
Ahmad R; Alam M; Hasegawa M; Uchida Y; Al-Obaid O; Kharbanda S; Kufe D
Mol Cancer; 2017 Feb; 16(1):33. PubMed ID: 28153010
[TBL] [Abstract][Full Text] [Related]
4. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells.
Alam M; Rajabi H; Ahmad R; Jin C; Kufe D
Oncotarget; 2014 May; 5(9):2622-34. PubMed ID: 24770886
[TBL] [Abstract][Full Text] [Related]
5. MUC1 oncoprotein is a druggable target in human prostate cancer cells.
Joshi MD; Ahmad R; Yin L; Raina D; Rajabi H; Bubley G; Kharbanda S; Kufe D
Mol Cancer Ther; 2009 Nov; 8(11):3056-65. PubMed ID: 19887552
[TBL] [Abstract][Full Text] [Related]
6. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.
Raina D; Kosugi M; Ahmad R; Panchamoorthy G; Rajabi H; Alam M; Shimamura T; Shapiro GI; Supko J; Kharbanda S; Kufe D
Mol Cancer Ther; 2011 May; 10(5):806-16. PubMed ID: 21421804
[TBL] [Abstract][Full Text] [Related]
7. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
Yin L; Kufe T; Avigan D; Kufe D
Blood; 2014 May; 123(19):2997-3006. PubMed ID: 24632713
[TBL] [Abstract][Full Text] [Related]
8. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
[TBL] [Abstract][Full Text] [Related]
9. MUC1-C is a target in lenalidomide resistant multiple myeloma.
Yin L; Tagde A; Gali R; Tai YT; Hideshima T; Anderson K; Avigan D; Kufe D
Br J Haematol; 2017 Sep; 178(6):914-926. PubMed ID: 28643330
[TBL] [Abstract][Full Text] [Related]
10. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells.
Raina D; Ahmad R; Joshi MD; Yin L; Wu Z; Kawano T; Vasir B; Avigan D; Kharbanda S; Kufe D
Cancer Res; 2009 Jun; 69(12):5133-41. PubMed ID: 19491255
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.
Uchida Y; Raina D; Kharbanda S; Kufe D
Cancer Biol Ther; 2013 Feb; 14(2):127-34. PubMed ID: 23114713
[TBL] [Abstract][Full Text] [Related]
12. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
14. Specific targeting of tumor cells by lyophilisomes functionalized with antibodies.
van Bracht E; Stolle S; Hafmans TG; Boerman OC; Oosterwijk E; van Kuppevelt TH; Daamen WF
Eur J Pharm Biopharm; 2014 May; 87(1):80-9. PubMed ID: 24463217
[TBL] [Abstract][Full Text] [Related]
15. Sustained release of PTX-incorporated nanoparticles synergized by burst release of DOX⋅HCl from thermosensitive modified PEG/PCL hydrogel to improve anti-tumor efficiency.
Xu S; Wang W; Li X; Liu J; Dong A; Deng L
Eur J Pharm Sci; 2014 Oct; 62():267-73. PubMed ID: 24931190
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target.
Raina D; Agarwal P; Lee J; Bharti A; McKnight CJ; Sharma P; Kharbanda S; Kufe D
PLoS One; 2015; 10(8):e0135156. PubMed ID: 26267657
[TBL] [Abstract][Full Text] [Related]
17. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
[TBL] [Abstract][Full Text] [Related]
18. A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity.
Liu J; Qiu Z; Wang S; Zhou L; Zhang S
Biomed Mater; 2010 Dec; 5(6):065002. PubMed ID: 20924138
[TBL] [Abstract][Full Text] [Related]
19. Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation.
Huo ZJ; Wang SJ; Wang ZQ; Zuo WS; Liu P; Pang B; Liu K
Cancer Sci; 2015 Oct; 106(10):1429-37. PubMed ID: 26177628
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.
Lv S; Tang Z; Li M; Lin J; Song W; Liu H; Huang Y; Zhang Y; Chen X
Biomaterials; 2014 Jul; 35(23):6118-29. PubMed ID: 24794923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
